Fibrogen, Inc. shares rise 27.00% premarket after reporting earnings and positive updates on China sale and clinical trials.

Fibrogen, Inc. rose 27.00% in premarket trading, driven by several positive news events. The company reported earnings results for the second quarter, with the total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $210 million, a $50 million increase from initial guidance. Additionally, the company announced the initiation of a Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC), expected in 3Q 2025. The company also reached an agreement with the U.S. Food and Drug Administration (FDA) on important design elements for a pivotal Phase 3 trial for roxadustat for the treatment of anemia in patients.